Inhibikase Therapeutics Inc R&D Event Transcript
Well, thank you, everyone, for joining the live webcast of Inhibikase Therapeutics 2023 R&D Day. Today's work will be focused on neurodegeneration. Last week, last Wednesday, we put out a press release that discussed our recent updates on our IkT-001Pro program that is focused on an alternate form of delivery of the anticancer agent, imatinib mesylate, a technology development program for us.
With us today are myself, Dr. Milton Werner, President and Chief Executive Officer; and Joe Frattaroli, our Chief Financial Officer. Joe, why don't you say hi for a second.
Hi. I want to thank everybody for taking the time today. I know we're all busy, so appreciate everybody out participating.
So we all know that it's a pretty volatile time in the market, Inhibikase has had quite a number of swings in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
